益脉康分散片联合胰激肽原酶治疗糖尿病视网膜病变的疗效观察

目的探讨益脉康分散片联合胰激肽原酶治疗糖尿病视网膜病变的临床疗效。方法选取2014年1月—2016年1月上海市杨浦区五角场镇社区卫生服务中心收治的糖尿病视网膜病变患者88例,根据治疗方法不同分成对照组和治疗组,每组各44例。对照组口服胰激肽原酶肠溶片,2片/次,3次/d。治疗组在对照组基础上口服益脉康分散片,2片/次,3次/d。两组患者均治疗3个月。观察两组的临床疗效,比较两组的血液流变学、血糖、血脂及眼部血流动力学情况。结果治疗后,对照组和治疗组的总有效率分别为81.82%、95.45%,两组比较差异有统计学意义(P0.05)。治疗后,两组血细胞比容(HCT)、纤维蛋白原(FIB)、红细胞聚集指数(RF)、全血高切黏度(HS)均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的降低程度明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组三酰甘油和总胆固醇均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的降低程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组眼动脉(OA)、视网膜中央动脉(CRA)、睫状后动脉(PCA)的收缩期峰值流速(PSV)和舒张末期流速(EDV)均显著升高,而阻力指数(RI)均降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论益脉康分散片联合胰激肽原酶治疗糖尿病视网膜病变具有较好的临床疗效,可改善血液流变学和眼部血流动力学,降低血脂水平,具有一定的临床推广应用价值。

Clinical observation of Yimaikang Dispersible Tablets combined with pancreatic kininogenase in treatment of diabetic retinopathy

Objective To investigate the clinical effect of Yimaikang Dispersible Tablets combined with pancreatic kininogenase in treatment of diabetic retinopathy. Methods Patients (88 cases) with diabetic retinopathy in Shanghai Yangpu District Wujiaochang Town Community Health Service Center from January 2014 to January 2016 were enrolled in this study. According to the different treatment plan, patients were divided into the control and treatment groups, and each group had 44 cases. Patients in the control group were po administered with Pancreatic Kininogenase Enteric-coated Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Yimaikang Dispersible Tablets on the basis of the control group, 2 tablets/time, three times daily. After treatment, the clinical efficacies were evaluated, blood rheology, blood glucose, blood lipid, and hemodynamic parameters in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.82% and 95.45%, respectively, and there was difference between two groups (P<0.05). After treatment, HCT, FIB, RF, and HS in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, triglyceride and total cholesterol in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, PSV and EDV of OA, CRA, and PCA in two groups were significantly increased, but the RI of OA, CRA, and PCA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Yimaikang Dispersible Tablets combined with pancreatic kininogenase has clinical curative effect in treatment of diabetic retinopathy, and can improve blood rheology and ocular hemodynamics, reduce blood lipid level, which has a certain clinical application value.